INNATE PHARMA SA Aktie

1,73 EUR +0,04 EUR +2,37 %

09:47:44

STU

1,74 EUR +0,03 EUR +1,87 %

01.10.2025

PAR

INNATE PHARMA SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.157,42 Mio. EUR

Div. Rendite0,00%

WKNA0LCUJ

ISINFR0010331421

SymbolIPHYF

INNATE PHARMA SA Aktien News

Sortieren:Datum Meistgelesen

06.03.24BusinesswireInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

21.02.24BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conference

12.01.24BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024

04.01.24BusinesswireInnate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

04.01.24BusinesswireInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

19.12.23BusinesswireInnate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

11.12.23BusinesswireInnate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

10.12.23BusinesswireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

27.11.23BusinesswireInnate Pharma to Host Virtual KOL Event on Lacutamab

14.11.23BusinesswireInnate Pharma Reports Third Quarter 2023 Financial Results and Business Update

07.11.23BusinesswireInnate Pharma Announces Conference Call for Third Quarter 2023 Business Update

03.11.23BusinesswireInnate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

27.10.23BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conferences

19.10.23BusinesswireInnate Pharma 2024 Financial Calendar

16.10.23BusinesswireInnate Pharma Announces Abstracts Selected for ESMO Congress 2023

09.10.23BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of October 3, 2023

05.10.23BusinesswireInnate Pharma Provides Update on Lacutamab Clinical Program

14.09.23BusinesswireInnate Pharma Reports First Half 2023 Financial Results and Business Update

29.08.23BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update

10.08.23BusinesswireInnate Pharma to Participate in Upcoming Investor Conference

11.07.23BusinesswireFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

07.07.23BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023

26.06.23BusinesswireFirst Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

16.06.23BusinesswireInnate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

12.06.23BusinesswireInnate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma

10.06.23BusinesswireInnate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

08.06.23BusinesswireSAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

07.06.23BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of June 1, 2023

26.05.23BusinesswireInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML

23.05.23BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences

15.05.23BusinesswireInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress

12.05.23BusinesswireOutcome of Innate Pharma’s 2023 Annual General Meeting

10.05.23BusinesswireInnate Pharma Reports First Quarter 2023 Financial Results and Business Update

09.05.23BusinesswireNumber of shares and voting rights of Innate Pharma as of May 1, 2023

03.05.23BusinesswireInnate Pharma Announces Conference Call and Webcast for Q1 Business Update

03.05.23BusinesswireInnate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

26.04.23BusinesswireInnate Pharma Establishes a New At-The-Market ("ATM”) Program on Nasdaq

21.04.23BusinesswireInnate Pharma to Participate in Upcoming Investor Conference

18.04.23BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of April 1, 2023

07.04.23BusinesswireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023

INNATE PHARMA SA News

INNATE PHARMA SA News: auf dieser Seite finden Sie alle INNATE PHARMA SA News und Nachrichten zur INNATE PHARMA SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch INNATE PHARMA SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um INNATE PHARMA SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.